(Q63571329)

English

Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor (English)

0 references

sponsor

National Cancer Institute

0 references

country

Canada

0 references

United States of America

0 references

start time

13 October 2016

0 references

end time

31 August 2019

0 references

number of participants

36

0 references

research intervention

osimertinib

0 references

clinical trial phase

phase I clinical trial

0 references

research site

Yale University

0 references

University of South Florida

0 references

University of Toronto

0 references

minimum age

18 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT02503722

0 references

(Q63571329)

Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)